Your browser doesn't support javascript.
loading
Levistilide A ameliorates neuroinflammation via inhibiting JAK2/STAT3 signaling for neuroprotection and cognitive improvement in scopolamine-induced Alzheimer's disease mouse model.
Ni, Haojie; Liao, Yanfang; Zhang, Yifan; Lu, Huinian; Huang, Zhiju; Huang, Fengming; Zhang, Zhende; Dong, Yan; Wang, Zihao; Huang, Yujie.
Afiliación
  • Ni H; Science and Technology Innovation Center, Guangzhou University of Chinese Medicine, Guangzhou 510405, China.
  • Liao Y; Science and Technology Innovation Center, Guangzhou University of Chinese Medicine, Guangzhou 510405, China.
  • Zhang Y; Science and Technology Innovation Center, Guangzhou University of Chinese Medicine, Guangzhou 510405, China.
  • Lu H; College of Pharmacy, Shenzhen Technology University, Shenzhen 518118, China.
  • Huang Z; College of Pharmacy, Shenzhen Technology University, Shenzhen 518118, China.
  • Huang F; College of Pharmacy, Shenzhen Technology University, Shenzhen 518118, China.
  • Zhang Z; College of Pharmacy, Shenzhen Technology University, Shenzhen 518118, China.
  • Dong Y; Science and Technology Innovation Center, Guangzhou University of Chinese Medicine, Guangzhou 510405, China. Electronic address: 1462523594@qq.com.
  • Wang Z; School of Chinese Medicine, Hong Kong Baptist University, Hong Kong Special Administrative Region. Electronic address: wangzh21@hkbu.edu.hk.
  • Huang Y; College of Pharmacy, Shenzhen Technology University, Shenzhen 518118, China. Electronic address: huangyujie@sztu.edu.cn.
Int Immunopharmacol ; 124(Pt A): 110783, 2023 Nov.
Article en En | MEDLINE | ID: mdl-37619415
Alzheimer's disease (AD) is a progressive neurodegenerative disease associated with cognitive impairment and dementia, which has become a major public health problem. There are no effective therapeutic agents used to treat AD in clinic for the extremely complex pathogenesis. Here we identify Levistilide A (LA), one of the major active natural terpene lactone constituents from Chinese herbal medicine Angelicae sinensis and Chuanxiong Rhizoma, as a potent neuroinflammation inhibitor for neuroprotection and cognitive improvement of AD. We show that LA suppresses neuronal apoptosis, restores cholinergic system function, and lowers neuroinflammation in vivo to improve scopolamine (SCOP)-induced learning and memory deficits. In addition, LA inhibits the release of IL-1ß, IL-6 and TNF-α, while increasing the production of IL-4 and IL-10 for anti-inflammatory effects in LPS or Aß-induced BV2 and HMC3 cells. Furthermore, the conditioned medium (CM) from LA-treated BV2 or HMC3 cells enhances the viability of SH-SY5Y and HT-22 cells, and LA reverses M1 to M2 phenotype transformation of BV2 and HMC3 cells accompanied by the inhibited Iba-1 expression and mRNA level of IL-1ß, IL-6, TNF-α and NOS2, and the increased expression of ARG1, CD206 and CD163. Mechanistically, we analyze JAK2/STAT3 signaling as possible targets of LA using network pharmacology approaches, and further experimentally validate that LA inhibits the phosphorylation of JAK2 and STAT3, and STAT3 expression within nucleus both in vitro and in vivo. Collectively, we identify LA as a potential neuroinflammation inhibitor for neuroprotection and cognitive improvement, which is expected to be a candidate for AD therapy.
Palabras clave

Texto completo: 1 Bases de datos: MEDLINE Idioma: En Revista: Int Immunopharmacol Año: 2023 Tipo del documento: Article País de afiliación: China

Texto completo: 1 Bases de datos: MEDLINE Idioma: En Revista: Int Immunopharmacol Año: 2023 Tipo del documento: Article País de afiliación: China